Strategic parten Bionovis actively pursues global partnerships and collaborations with leading industry players and national public institutions, presenting a clear opening for co-development, technology transfer, and joint R&D opportunities in biosimilars, biobetters, and innovative biologics.

Public health focus Recent MoUs and commitments with Fiocruz, Farmanguinhos, BahiaFarma, Biocon Biologics, and Bionovis for production of high-value biologics like Pertuzumab indicate readiness to scale manufacturing for national public health systems, creating channels for large-volume procurement and long-term supply contracts.

Pipelines opportunity Bionovis is building a diversified pipeline that includes biosimilars, biobetters, and innovative biopharmaceuticals, which aligns with client needs for a steady stream of near-term and mid-term biologics assets to bolster their product portfolios.

Manufacturing capability With a focus on establishing complete bioprocess technology for monoclonal antibodies and therapeutic proteins, there is potential to accelerate CDMO-type collaborations, tech transfer, and capacity expansion deals leveraging their world-class infrastructure.

Brazilian market access Being a 100 Brazilian biotech firm with national collaborations and public-sector exposure, Bionovis offers a strategic route for regional market entry, pricing leverage, and government-funded tender opportunities for complex biologics.